Cargando…

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is related to subclinical atherosclerosis. However, whether the severity of the disease (or which histopathological component) is associated with subclinical atherosclerosis remains controversial. This study aimed to investigate the association between the hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Kato, Keizo, Abe, Hiroshi, Ono, Hirotaka, Kawano, Tadamichi, Yoshida, Yuji, Tanabe, Tomohide, Okubo, Tomomi, Hayama, Korenobu, Nakagawa-Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Emoto, Naoya, Nagao, Mototsugu, Inagaki, Kyoko, Fukuda, Izumi, Sugihara, Hitoshi, Iwakiri, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342487/ https://www.ncbi.nlm.nih.gov/pubmed/34354193 http://dx.doi.org/10.1038/s41598-021-95581-8

Ejemplares similares

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2019)

Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
por: Arai, Taeang, et al.
Publicado: (2022)

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
por: Arai, Taeang, et al.
Publicado: (2021)

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial
por: Okubo, Tomomi, et al.
Publicado: (2021)

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
por: Arai, Taeang, et al.
Publicado: (2022)

Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease
por: Kawano, Tadamichi, et al.
Publicado: (2022)

How do the 2022 European Society of Cardiology/European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis
por: Atsukawa, Masanori, et al.
Publicado: (2023)

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C
por: Yoshida, Yuji, et al.
Publicado: (2023)

Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2021)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Influencing factors on serum 25-hydroxyvitamin D(3) levels in Japanese chronic hepatitis C patients
por: Atsukawa, Masanori, et al.
Publicado: (2015)

Usefulness of autotaxin for the complications of liver cirrhosis
por: Shao, Xue, et al.
Publicado: (2020)

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
por: Atsukawa, Masanori, et al.
Publicado: (2013)

A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C
por: Atsukawa, Masanori, et al.
Publicado: (2021)

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
por: Kato, Keizo, et al.
Publicado: (2019)

Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Kumagai, Erina, et al.
Publicado: (2016)

Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure
por: Shirakabe, Akihiro, et al.
Publicado: (2022)

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression
por: Masu, Takushi, et al.
Publicado: (2018)

Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Shoji, Hirotaka, et al.
Publicado: (2016)

Influencing Factors and Molecular Pathogenesis of Sarcopenia and Osteosarcopenia in Chronic Liver Disease
por: Saeki, Chisato, et al.
Publicado: (2021)

A case of pheochromocytoma associated with liver abscess and intestinal pseudo-obstruction
por: Okazaki-Hada, Mikiko, et al.
Publicado: (2022)

Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
por: Yilmaz, Yusuf, et al.
Publicado: (2011)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Sclerosed Hemangioma Accompanied by Multiple Cavernous Hemangiomas of the Liver
por: Yuki, Michiko, et al.
Publicado: (2015)

Ruptured Amebic Liver Abscess
por: Kawano, Toyokazu, et al.
Publicado: (1990)

Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
por: Lin, Shu-Hsien, et al.
Publicado: (2022)

Clinical characteristics of sarcopenia in patients with alcoholic liver cirrhosis
por: Saeki, Chisato, et al.
Publicado: (2021)

Increased Frequency of Dysfunctional Siglec-7(−)CD57(+)PD-1(+) Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease
por: Sakamoto, Yuzuru, et al.
Publicado: (2021)

The lymphatic system in alcohol-associated liver disease
por: Kondo, Reiichiro, et al.
Publicado: (2020)

Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease
por: Alsaif, Faisal A., et al.
Publicado: (2020)

The role of YAP1 in liver cancer stem cells: proven and potential mechanisms
por: Wu, Haofeng, et al.
Publicado: (2022)

Effects of denosumab treatment in chronic liver disease patients with osteoporosis
por: Saeki, Chisato, et al.
Publicado: (2020)

Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects
por: Ma, D W L, et al.
Publicado: (2016)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Relationship between Osteosarcopenia and Frailty in Patients with Chronic Liver Disease
por: Saeki, Chisato, et al.
Publicado: (2020)

Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase
por: Iwakiri, Yasuko
Publicado: (2015)

Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease
por: Sun, Qing-Feng, et al.
Publicado: (2022)

Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography
por: Taibbi, Adele, et al.
Publicado: (2021)

Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
por: Kawata, Kazuhito, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rvf5n07j7sin4aass5qo3uh3bi